{"title":"Arenobufagin induces cell apoptosis by modulating the cell cycle regulator claspin and the JNK pathway in nasopharyngeal carcinoma cells.","authors":"Hsin-Yu Ho, Mu-Kuan Chen, Chia-Chieh Lin, Yu‐Sheng Lo, Yi‐Ching Chuang, Ming-Ju Hsieh","doi":"10.1080/14728222.2024.2348014","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nThe high recurrence rate and incidence of distant metastasis of nasopharyngeal carcinoma (NPC) result in poor prognosis. Natural compounds that can complement combination radiation therapy need to be identified. Arenobufagin is commonly used for heart diseases and liver cancer, but its effectiveness in NPC is unclear.\n\n\nSTUDY DESIGN AND METHODS\nThe effect of arenobufagin-induced apoptosis was measured by a cell viability assay, tumorigenic assay, fluorescence assay, and Western blot assay through NPC-039 and NPC-BM cell lines. The protease array, Western blot assay, and transient transfection were used to investigate the underlying mechanism of arenobufagin-induced apoptosis. A NPC xenograft model was established to explore the antitumor activity of arenobufagin in vivo.\n\n\nRESULTS\nOur findings indicated that arenobufagin exerted cytotoxic effects on NPC cells, inhibiting proliferation through apoptosis activation. The downregulation of claspin was confirmed in arenobufagin-induced apoptosis. The combined treatment of arenobufagin and inhibitors of mitogen-activated protein kinase demonstrated that arenobufagin induced NPC apoptosis through the c-Jun N-terminal kinases (JNK) pathway inhibition. Furthermore, arenobufagin suppressed NPC tumor proliferation in vivo.\n\n\nCONCLUSION\nOur results revealed the antitumor effect of arenobufagin in vitro and in vivo. Arenobufagin may provide clinical utility on NPC due to the suppression of claspin and the JNK pathway.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2024.2348014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
The high recurrence rate and incidence of distant metastasis of nasopharyngeal carcinoma (NPC) result in poor prognosis. Natural compounds that can complement combination radiation therapy need to be identified. Arenobufagin is commonly used for heart diseases and liver cancer, but its effectiveness in NPC is unclear.
STUDY DESIGN AND METHODS
The effect of arenobufagin-induced apoptosis was measured by a cell viability assay, tumorigenic assay, fluorescence assay, and Western blot assay through NPC-039 and NPC-BM cell lines. The protease array, Western blot assay, and transient transfection were used to investigate the underlying mechanism of arenobufagin-induced apoptosis. A NPC xenograft model was established to explore the antitumor activity of arenobufagin in vivo.
RESULTS
Our findings indicated that arenobufagin exerted cytotoxic effects on NPC cells, inhibiting proliferation through apoptosis activation. The downregulation of claspin was confirmed in arenobufagin-induced apoptosis. The combined treatment of arenobufagin and inhibitors of mitogen-activated protein kinase demonstrated that arenobufagin induced NPC apoptosis through the c-Jun N-terminal kinases (JNK) pathway inhibition. Furthermore, arenobufagin suppressed NPC tumor proliferation in vivo.
CONCLUSION
Our results revealed the antitumor effect of arenobufagin in vitro and in vivo. Arenobufagin may provide clinical utility on NPC due to the suppression of claspin and the JNK pathway.
期刊介绍:
The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.
The Editors welcome:
Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.
Articles should not include clinical information including specific drugs and clinical trials.
Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.
The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.